利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

75 条记录 (耗时 0.026 秒)

    Substituted derivatives of 20,21-dinoreburnamenine, their use as medicaments and the pharmaceutical compositions containing them
    1.
    发明授权
    Substituted derivatives of 20,21-dinoreburnamenine, their use as medicaments and the pharmaceutical compositions containing them 失效
    其作为药物和含有它们的药物组合物的二十二碳三烯酸的取代衍生物

    公开(公告)号：US5093337A

    公开(公告)日：1992-03-03

    申请号：US391511

    申请日：1989-07-18

    申请人： Nurgun Aktogu ,  Francois Clemence ,  Claude Oberlander

    发明人： Nurgun Aktogu ,  Francois Clemence ,  Claude Oberlander

    IPC分类号： C07D461/00 ,  A61K20060101 ,  A61K31/435 ,  A61K31/445 ,  A61K31/475 ,  A61K31/495 ,  A61P9/08 ,  A61P9/10 ,  A61P25/00 ,  A61P25/24 ,  A61P25/26 ,  C07D20060101

    CPC分类号： C07D461/00

    摘要： The invention concerns compounds of formula (I); ##STR1## in which R.sub.1, R.sub.2 and R.sub.3, identical or different, stand for hydrogen, halogen, alkyl or alkoxy (C.sub.1-5), hydroxy, trifluoromethyl, nitro, amino, alkylamino, dialkylamino, acylamino, R.sub.1, R.sub.2 and R.sub.3 being unable to stand for hydrogen simultaneously and in which (a) stands for (b), (c), or (d), all possible isomeric forms of said products of formula (I) being racemic or optically active, as well as their additional salts with acids, their preparation and the new intermediate products obtained, their application as drugs in particular nootropes, antidepressants, neuronal protectors, anti-anoxics, anti-ischemics, and the compositions containing them.

    摘要翻译： PCT No.PCT / FR88 / 00562 Sec。 371日期：1989年7月18日 102（e）日期1989年7月18日PCT提交1988年11月16日PCT公布。 出版物WO89 / 04830 日期：1989年6月1日。本发明涉及式（I）化合物。 其中R1，R2和R3相同或不同，代表氢，卤素，烷基或烷氧基（C1-5），羟基，三氟甲基，硝基，氨基，烷基氨基，二烷基氨基，酰基氨基， R1，R2和R3不能同时代表氢，其中（a）代表（b），（c）或（d），所有式（I）产物的所有可能的异构形式是外消旋或光学活性的 以及它们与酸的附加盐，它们的制备和获得的新的中间产物，它们作为药物特别是助推剂，抗抑郁药，神经元保护剂，抗缺氧剂，抗缺血剂以及含有它们的组合物的应用。

    17-aza-20,21, dinoreburnamenines
    5.
    发明授权
    17-aza-20,21, dinoreburnamenines 失效
    17-aza-20,21，二溴柏宁

    公开(公告)号：US4886802A

    公开(公告)日：1989-12-12

    申请号：US181657

    申请日：1988-04-14

    申请人： Nurgun Aktogu ,  Francois Clemence

    发明人： Nurgun Aktogu ,  Francois Clemence

    IPC分类号： C07D209/16 ,  A61K31/495 ,  A61P9/00 ,  A61P25/02 ,  A61P25/04 ,  C07D209/14 ,  C07D401/06 ,  C07D403/06 ,  C07D471/14 ,  C07D471/22

    CPC分类号： C07D403/06 ,  C07D209/14 ,  C07D471/14

    摘要： A compound selected from the group consisting of all possible isomeric forms, optically active isomers and racemic mixtures of compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 are individually selected from the group consisting of hydrogen, halogen, alkyl and alkoxy of 1 to 5 carbon atoms, --OH, --CF.sub.3 and --NO.sub.2, R is selected from the group consisting of hydrogen, alkyl of 1 to 5 carbon atoms, aralkyl of 7 to 12 carbon atoms, benzoyl and acyl of an alkanoic acid of 1 to 12 alkyl carbon atoms and ##STR2## is selected from the group consisting of ##STR3## and their non-toxic, pharmaceutically acceptable acid addition salts having analgesic activity as well as cerebral oxygenating and vaso regulating activity.

    摘要翻译： 选自下列化合物的化合物：所有可能的异构体形式，光学活性异构体和式I化合物的外消旋混合物，其中R 1和R 2分别选自氢，卤素，烷基和烷氧基， 5个碳原子，-OH，-CF 3和-NO 2，R选自氢，1至5个碳原子的烷基，7至12个碳原子的芳烷基，苯甲酰基和1至12个链烷酸的酰基 烷基碳原子和选自 + TR 及其具有止痛活性以及脑氧合和血管调节活性的无毒的药学上可接受的酸加成盐。

    Decahydroquinolines and central analgesic method of use thereof
    10.
    发明授权
    Decahydroquinolines and central analgesic method of use thereof 失效
    十氢喹啉和中枢镇痛药的使用方法

    公开(公告)号：US4877796A

    公开(公告)日：1989-10-31

    申请号：US084456

    申请日：1987-08-12

    申请人： Francois Clemence ,  Odile Le Martret ,  Francoise Delevallee ,  Michel Fortin

    发明人： Francois Clemence ,  Odile Le Martret ,  Francoise Delevallee ,  Michel Fortin

    IPC分类号： A61K31/47 ,  A61P7/06 ,  A61P7/10 ,  A61P9/06 ,  A61P9/12 ,  A61P25/04 ,  C07D215/40 ,  C07D401/12 ,  C07D409/12

    CPC分类号： C07D215/40

    摘要： A compound selected from the group consisting of all enantiomeric and diastereoisomeric forms of a decahydroquinoline of the formula ##STR1## wherein R.sub.1 is alkyl of 1 to 5 carbon atoms, R.sub.2 is selected from the group consisting of hydrogen and akyl of 1 to 5 carbon atoms, A is selected from the group consisting of --(CH.sub.2).sub.n --, --CH.sub.2 O-- and alkylene substituted with alkyl having a total of 2 to 8 carbon atoms, n is an integer from 0 to 5, Z is selected from the group consisting of optionally substituted phenyl, optionally substituted naphthyl, optionally substituted indenyl, optionally substituted heteromonocycle of 5 to 6 members and optionally substituted heterobicycle with the proviso that when Z is o-alkoxy-phenyl, A is not --(CH.sub.2).sub.n -- in which n is O, and their non-toxic, pharmaceutically acceptable acid addition salts and their quaternary ammonium salts and intermediates having analgesic, diuretic, hypotensive, anti-arrithmic and anti-cerebral-ischaemic properties.

    摘要翻译： 选自下式的化合物：其中R 1为1至5个碳原子的烷基，R 2选自氢和1至5个碳原子的烷基的所有对映异构体和非对映异构体形式的十氢喹啉的化合物 原子，A选自 - （CH 2）n - ， - CH 2 O-和被具有总共2至8个碳原子的烷基取代的亚烷基，n是0至5的整数，Z选自 由任选取代的苯基，任选取代的萘基，任选取代的茚基，任选取代的5至6个成员的异单环和任选取代的杂双环，条件是当Z是邻 - 烷氧基 - 苯基时，A不是 - （CH2）n-，其中 n是O，它们的无毒的药学上可接受的酸加成盐及其季铵盐和具有止痛，利尿，降压，抗对数和抗脑缺血性质的中间体。